Tag:
V710
Latest Headlines
Latest Headlines
In fresh blow, Intercell and Merck dump Ph2/3 vaccine study
Just about two months after Intercell CEO Gerd Zettlmeissl insisted that the decision to halt patient recruitment for a Phase II/III trial of its experimental vaccine V710 did not signal the end of
Intercell shares nosedive as investigators slam brakes on patient recruitment
Austria's Intercell ( $ICLL ) saw its stock take another nasty dive after a safety panel warned investigators against recruiting more patients for a Phase II/III clinical trial of an experimental
